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Introduction 
Influenza A infection may cause severe exacerbations of 
asthma with increased airway responsiveness and airflow 
obstruction (1). Annual vaccination against influenza is 
therefore recommended for patients with asthma by the 
Chief Medical Officer of the Department of Health. How- 
ever, some patients report exacerbations of their asthma, 
apparently related to influenza vaccination, and there is 
reluctance to adhere to the recommended vaccination 
policy (2). We therefore studied the effect of a current 
subunit vaccine on symptoms, medication use, spirometry 
and airway responsiveness in patients with stable asthma. 
Patients, Methods and Results 
Twenty-two patients (eight male) with a median age of 41 
(range 19-71) years participated in the study, which was 
undertaken in November 1995. All had a forced expiratory 
volume in 1 s (FEV,) of greater than 60% of the predicted 
value (range 60-l 12%); all had demonstrated > 15% revers- 
ibility and all were taking inhaled p2 agonists; 20 were 
taking inhaled corticosteroids. All were non-smokers and 
13 had previously received influenza vaccination. All medi- 
cations were continued unchanged during the study. 
Spirometry and airway responsiveness (PD,, methacholine) 
(3) were measured twice at a 2 week interval before vacci- 
nation and at 48 and 96 h postvaccination. Patients were 
assigned in a double-blind fashion to receive either placebo 
(n=5) or 0.5 ml of inactivated surface antigen influenza 
vaccine (Evans Medical Ltd.) by deep subcutaneous injec- 
tion (n= 17). The vaccine contained surface antigens from 
the three strains of influenza virus recommended for 19951 
1996. Patients recorded symptoms, medication use and 
adverse events. 
Eight vaccine recipients reported transient symptoms 
such as fever, sore throat and malaise, and one developed a 
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reaction at the site of vaccination; no placebo recipient 
reported any adverse events. Symptoms were mild and 
resolved within 48 h. No patient reported any worsening 
of asthma symptoms or increase in medication use. There 
was no significant difference between mean pre- and post- 
vaccination spirometry or PD,, in either the placebo or 
active vaccination groups (analysis of variance, ANOVA) 
(Table 1) and no individual patient showed a change in 
postvaccination PD,, of more than two-fold. 
Discussion 
Infection with influenza A virus or vaccination with live 
attenuated influenza vaccine has been shown to cause 
increased airways responsiveness (1,2). Studies using older 
killed vaccines gave conflicting results, with some studies 
showing increased airways responsiveness post vaccination 
(4,5). More recent studies using modern purified surface 
sub-unit vaccines show no effect on airway responsiveness 
or asthma control (6). However, some patients still report 
exacerbations of their asthma, apparently related to influ- 
enza vaccination, and there is reluctance to adhere to the 
recommended annual vaccination policy (2). Our study 
showed no evidence of increased airway responsiveness or 
airway obstruction in patients with stable asthma receiving 
a modern purified surface antigen sub-unit vaccine. Airway 
responsiveness is a continuous variable which is distributed 
normally in the general population. In practice PD,, values 
<2OOpg are almost invariably associated with evidence of 
active asthma, whereas values > 1000 ,ug rarely are. Inhaled 
steroids usually result in an increase in PD,, value. The 
serial quantification of geometric mean levels of airway 
responsiveness as PD,, offers a powerful method of detect- 
ing any general effect on asthmatic activity. Repeatability 
data from earlier investigations suggest that as few as six 
subjects would provide an 80% chance of detecting a 
doubling of asthmatic activity (i.e. a halving of geometric 
mean PD,,) at the 5% level of significance, and 37 would 
detect a one and a half-fold increase (i.e. a 25% decrement 
in geometric mean PD,, (3). The present investigation 
consequently had the power to detect a one and a half to 
two-fold increase in asthmatic activity, though in fact no 
hint of any increase was seen. We therefore conclude that 
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TABLE 1. Mean FEV, and PD,, @g) methacholine pre- and postvaccination 
Pre-vaccine Pre-vaccine Postvaccine Postvaccine 
1 2 48 h 96 h 
Active vaccine FEV, 2.93 2.89 2.83 2.90 
(1) (1.464.67) (1.324.20) (1.474.54) (1.40-4.54) 
n=17 PD 20 105 135 102 101 
olg) (1 l-6400) (10-6400) (8-6400) (8-6400) 
Placebo FEV, 3.49 3.54 3.41 3.44 
(1) (2.16420) (2.184.78) (2.304.39) (2.20436) 
n=5 PDm) 242 198 320 344 
olg) (15-6400) (166400) (25-6400) (15-6400) 
this vaccine does not generally exert any adverse effect on 
asthma. This and previous similar studies are reassuring 
and provide support for adherence to current vaccination 
guidelines. Minor transient symptoms were common after 
vaccination but were not associated with any increase in 
airway responsiveness or airway obstruction. It is import- 
ant to distinguish such systemic symptoms from true 
exacerbations of asthma when patients report an adverse 
reaction to previous vaccination. 
Although this study shows that a surface antigen sub-unit 
influenza vaccine does not exert a general adverse effect on 
airway responsiveness in patients with asthma it does not 
exclude the possibility that an individual patient may 
develop an allergic reaction to an influenza vaccine. Differ- 
entiation of a true reaction to vaccination from coincidental 
exacerbations of asthma in such patients would probably 
require repeat vaccination of the patient under double-blind 
experimental conditions and such a study has not been 
performed. Furthermore different vaccines may have differ- 
ent effects, and changes in the vaccine components from 
year-to-year to allow for antigenic drift of the virus might 
be important. 
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